The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease

Trial Profile

The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Macitentan (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions
  • Acronyms MENSCH
  • Most Recent Events

    • 12 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 12 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top